Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end

Direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV) infection, achieving high rates (≥ 95%) of sustained virological response, with a good safety profile and high compliance rates. Consequently, it had been expected that viral clearance will reduce morbidity...

Descripción completa

Detalles Bibliográficos
Autores principales: Muzica, Cristina Maria, Stanciu, Carol, Huiban, Laura, Singeap, Ana-Maria, Sfarti, Catalin, Zenovia, Sebastian, Cojocariu, Camelia, Trifan, Anca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684455/
https://www.ncbi.nlm.nih.gov/pubmed/33268960
http://dx.doi.org/10.3748/wjg.v26.i43.6770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684455/
https://www.ncbi.nlm.nih.gov/pubmed/33268960
http://dx.doi.org/10.3748/wjg.v26.i43.6770

Ejemplares similares